Proactiveinvestors news media have interviewed Imagion Biosystems CEO Bob Proulx, who answers questions about the company’s early cancer detection technology, its place in the the medical imaging market, intellectual property protections, and more.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)